Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 784

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 784
---
  43,477 |   |     |      |  39,560 |   |
| Accumulated depreciation          |     |              | (36,187 | ) |     |      | (32,866 | ) |
| Total property and equipment, net |     | $            |   7,290 |   |     | $    |   6,694 |   |

Depreciation expense was $, $ and $ for the years ended December 31, 2024, 2023 and 2022.

Note 5 Related party short-term loans: On September 28, 2023 and November 15, 2023, the Company entered into a series of short term loan agreements (the “Short Term Loan Agreements”) with certain existing shareholders of the Company, including Ronald Hafner, the Company’s Chairman of the Board of Directors, Felix Grisard, Jürgen Bauer and Maria Nayvalt, providing for unsecured loans to the Company in the aggregate amount of CHF 1,375,000($ 1,510,989). The loans bear interest at a rate of 10% per annum and mature on the earlier of December 31, 2024, or a liquidity event with a strategic partner, as amended on March 18, 2024. In October 2024, the Company entered into debt forgiveness agreements with the holders of the related party short -termloans, pursuant to which the Company issued an aggregate of 290,518common shares, par value CHF 0.03per share, or the common shares, of the Company, at a conversion price of $ 5.65(rounded) per share, in full satisfaction of an

Annex F-16 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

aggregate amount of CHF 1,492,431($ 1,640,034) in loans and interest provided to the Company by the Lenders, or collectively, the Loans. This conversion was facilitated through an ordinary capital increase, providing the necessary shares for the debt holders, and was recorded at fair market value with no gain or loss recognized in the statement of operations.

Note 6

Other Accrued Liabilities:

The Company’s other accrued liabilities consisted of the following as of December 31, 2024 and 2023:

|                                        |     | December 31, |